Findings from the SWOG S2001 trial show that pembrolizumab plus olaparib did not significantly improve progression-free survival compared with olaparib alone as maintenance therapy in patients with metastatic pancreatic cancer harboring germline BRCA1/2 mutations.
Pharmacy Times interviews Allison Burns, PharmD, RPh, the CEO of End Mass Overdose (EMO) Health to discuss how medication stigma and bias can impact patient recovery.
Pharmacy Times interviews Allison Burns, PharmD, RPh, the CEO of End Mass Overdose (EMO) Health to discuss why patients struggle to access mental health and addiction treatment medications.
Elizabeth Budde, MD, discusses the phase 3 data behind the mosunetuzumab plus polatuzumab vedotin combination in the SUNMO trial.
Electronic patient-reported outcome (ePRO) monitoring platforms may improve symptom management, reduce hospitalizations, and help patients remain on cancer therapy longer through earlier intervention and continuous remote support.
GLP-1 receptor agonists may be associated with improved survival outcomes and lower recurrence rates among women with breast cancer, obesity, and type 2 diabetes.
Jessica Paulus, ScD, discusses emerging real-world evidence suggesting GLP-1 receptor agonists may be associated with improved survival outcomes across several cancer types, while emphasizing the need for prospective clinical research.
Pharmacy Times interviews Allison Burns, PharmD, RPh, the CEO of End Mass Overdose (EMO) Health to discuss how stigma from health care providers or frontline staff impacts patient willingness to seek or continue treatment.
Pharmacy Times interviews Allison Burns, PharmD, RPh, the CEO of End Mass Overdose (EMO) Health to discuss common myths and misconceptions surrounding antidepressants, antipsychotics, and medications for addiction treatment in congregate care settings.
SARC041 data shows the clinical benefits associated with abemaciclib in the treatment of patients with incredibly rare diseases.
Apalutamide plus androgen deprivation therapy significantly increased the curative success of radical prostatectomy in patients with localized prostate cancer.
APP-led benign hematology consult programs helped community oncology practices significantly reduce time to first appointment while strengthening interdisciplinary collaboration with pharmacists and physicians.
This interview discusses emerging immunotherapy trends at the 2026 ASCO Annual Meeting, including cancer vaccines, cell-based therapies, ADCs, and AI-driven immune profiling tools poised to reshape oncology care.
In an interview with Pharmacy Times at the Consortium of Multiple Sclerosis Centers 2026, Jacci Bainbridge, PharmD, FCCP, Professor Vice Chair for Research and Scholarship, Neurology Pharmacy, presenting on current evidence surrounding discontinuation and de-escalation of disease-modifying therapies in multiple sclerosis, discusses rethinking long-term MS therapy, de-escalation, biomarkers and the future of care for MS.
In an interview with Pharmacy Times at the Consortium of Multiple Sclerosis Centers 2026, Patricia K. Coyle, MD, a Director at the MS Center at Stony Brook Medicine, presenting on current evidence surrounding discontinuation and de-escalation of disease-modifying therapies in multiple sclerosis, discusses rethinking escalation strategies in relapsing MS.
Proteomic liquid biopsy technology may improve early breast cancer detection, guide targeted therapy selection, and support longitudinal treatment monitoring in oncology care.
Pharmacists play a big role in biomarker testing, patient selection, and counseling on immune checkpoint inhibitor therapy in endometrial cancer.
In an interview with Pharmacy Times at the Consortium of Multiple Sclerosis Centers 2026, Donald Langan, PharmD, MD, a Multiple Sclerosis and Clinical Neuroimmunology Fellow at Columbia University, presenting on the evolution of GLP-1 receptor agonists, discussed the future of GLP-1 therapies and the expansion of the pharmacist's role.
In an interview with Pharmacy Times at the Consortium of Multiple Sclerosis Centers 2026, Julie Kidd, PhD, MPH, BCPS, the director of clinical services at Blue Ridge Neurology, presenting on Supplements in Multiple Sclerosis, discussed what the pharmacist's role in MS supplement safety.
Pharmacists unpack easier access to PCSK9 inhibitors and inclisiran—smart prior auth, Medicare Part B nuances, and foundation help that cuts costs.
Paste the article text (or an excerpt), and I’ll generate a 150-character, 24-word max SEO meta description in present tense.
In an interview with Pharmacy Times at the Consortium of Multiple Sclerosis Centers 2026, Julie Kidd, PhD, MPH, BCPS, the director of clinical services at Blue Ridge Neurology, presenting on Supplements in Multiple Sclerosis, discussed what works and what doesn't in MS supplements.
Researchers discuss how GLP-1 receptor agonists may be associated with improved survival outcomes in breast cancer and what clinicians should consider as use of these therapies continues to grow.
In an interview with Pharmacy Times at the Consortium of Multiple Sclerosis Centers 2026, Stephanie Iyer, PhD, CPP, BCACP, a clinical pharmacist at University of North Carolina neurology clinic, presenting on management of High-risk multiple sclerosis patients, discussed what the pharmacist's role is in managing high-risk MS patients.
In an interview with Pharmacy Times at the Consortium of Multiple Sclerosis Centers 2026, Stephanie Iyer, PhD, CPP, BCACP, a clinical pharmacist at University of North Carolina neurology clinic presenting on management of High-risk multiple sclerosis patients, discussed safety, treatment, and emerging strategies.
Joe DePinto of McKesson outlines the workflow barriers slowing CGT migration to community oncology, the reimbursement reforms needed to scale access, and the pharmacist’s pivotal role in making it all work.
Joe DePinto of McKesson discusses how payers, providers, and employers diverge on CGT reimbursement—and why outcomes-based payment models may hold the key to broader patient access.
Adding immune checkpoint inhibitors to carboplatin and paclitaxel has become the new frontline standard for advanced or recurrent endometrial cancer.
This week's episode covers the White House's expansion of the TrumpRx.gov platform, the pharmacist's critical role in closing adult hepatitis B vaccination gaps, and new FDA approvals in immunology, oncology, and cardiovascular care.
